Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab 1L for Persistent/Recurrent/Metastatic Cervical Cancer
NCT06459687Phase 3Recruiting
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Socazolimab + Chemo ± Bev with Placebo + Chemo ± Bev (2 arms). Primary endpoint: Overall Survival up to 100 months. Started Nov 2024; status: recruiting.
02
Drugs
socazolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06459687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06459687.